GRI · GRI Bio Inc
United States · RS rating 10 · As of 2026-10-14
| Price | 1.40 USD |
|---|---|
| 1-day change | -9.7% |
| RS rating (overall / 1M / 3M / 12M) | 10 / 9 / 34 / 2 |
| Stage | Declining |
| Composite / Minervini / CANSLIM score | 27 / 6 / 51 |
| Industry group (rank) | Medical-Biomed/Biotech (167) |
| EPS growth Q/Q | +43.5% |
| Sales growth Q/Q | – |
| Distance from 52-week high | +97.8% |
| Market cap (USD) | $3.5M |